You are here

Article Text

Article menu
Download PDFPDF
Prevalence
Cross-sectional
Severe adverse reactions are rare with infusions of infliximab in a community setting

https://doi.org/10.1136/ebn1002

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests YY has been a consultant or speaker for BMS, Celgene, Centocor, Genentech, Merck, Pfizer, Roche and UCB.